Takehiko Kawanishi

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers.

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers.

Journal: Clinical pharmacology in drug development

Published: June 14, 2018

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Journal: Clinical pharmacokinetics

Published: December 08, 2017

Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.

Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.

Journal: British journal of clinical pharmacology

Published: November 07, 2017

MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.

MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.

Journal: Scientific reports

Published: July 10, 2017

Preemptive Living Donor Kidney Transplantation and Kidney Function at the Initial Hospital Visit: A Single-Center Case-Control Study.

Preemptive Living Donor Kidney Transplantation and Kidney Function at the Initial Hospital Visit: A Single-Center Case-Control Study.

Journal: Transplantation proceedings

Published: September 19, 2015

A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

Journal: Blood

Published: June 10, 2015

Erratum to: Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment.

Erratum to: Application of Modeling and Simulation to a Long-Term Clinical Trial: A Direct Comparison of Simulated Data and Data Actually Observed in Japanese Osteoporosis Patients Following 3-Year Ibandronate Treatment.

Journal: Clinical pharmacokinetics

Published: March 21, 2015

Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment.

Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment.

Journal: Clinical pharmacokinetics

Published: November 19, 2014

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.

Journal: European journal of drug metabolism and pharmacokinetics

Published: August 26, 2014

Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.

Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.

Journal: Journal of clinical pharmacy and therapeutics

Published: February 17, 2014

Modeling and simulation of orlistat to predict weight loss and weight maintenance in obesity patients.

Modeling and simulation of orlistat to predict weight loss and weight maintenance in obesity patients.

Journal: Drug metabolism and pharmacokinetics

Published: January 15, 2014

Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor.

Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor.

Journal: The Journal of pharmacy and pharmacology

Published: November 05, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026